Ilesol Pharmaceuticals is proud to announce the launch of new products in our line-up and brand new web site. In addition to our current product lines CBD products, cosmetic products, and cosmetic ingredients, new innovative offerings will include botanical extracts, functional mushrooms, and customized food supplements, providing a diverse range of health and wellness solutions for our customers. With this expansion, Ilesol Pharmaceuticals aims to cater to a broader audience and deliver top-quality, natural alternatives for holistic health and wellbeing. Botanical Extracts: The new range of b ..read more

Ilesol Pharmaceuticals is proud to announce that EIHA’s CBD isolate dossier, RP427, has finally been validated by the UK’s Food Standards Agency (FSA), after a long-awaited process. This validation marks an important milestone for our company and for all members of Novel Food Consortium. We are excited to move to the next stage of the process – the risk assessment stage. Moving forward, we are eager to continue working with the FSA during the risk assessment stage. This stage will involve the FSA reviewing and assessing the toxicological data that we have submitted. We are confident that our s ..read more

Law Library of US Congress Releases Comprehensive Global Hemp Regulation Report   The Law Library of Congress has released an extensive 137-page report titled “Regulation of Hemp,” which delves into the regulatory landscape of hemp in 14 selected jurisdictions, including Australia, Brazil, Canada, China, Colombia, Ecuador, Israel, India, Japan, New Zealand, Russia, the Slovak Republic, the United Kingdom, and the European Union. Additionally, the report provides an overview of hemp regulations in more than 90 countries worldwide. Published in November 2022, the report was recently highlig ..read more

Diabetic cardiomyopathy (DCM) is a prevalent cardiovascular complication arising from diabetes, characterized by cardiac dysfunction, fibrosis, oxidative stress, inflammation, and increased cell death. The study investigates the potential therapeutic effects of cannabidiol (CBD), a non-psychoactive compound derived from the Cannabis plant, on DCM in a rat model of type 1 diabetes. The authors induced diabetes in male Wistar rats by administering streptozotocin (STZ), a substance that selectively destroys pancreatic beta cells. Rats were then treated with CBD (1, 10 and 20 mg/kg daily), for 4-1 ..read more

The latest scientific findings have shed light on the role of the cannabinoid receptor in reducing negative ketamine side effects, confirm the risks of psychosis and cannabis use disorder among high potency cannabis consumers, and establish a new case of successful treatment of an autistic child with CBD. The cannabinoid receptor type 1 mediates the psychostimulant side effects induced by ketamine The antidepressant properties of ketamine have been demonstrated in both experimental and clinical studies, but the psychotomimetic side effects still limit its wider use as an antidepressant. The ne ..read more

Ilesol Pharmaceuticals has launched three new skincare products as a part of our Skin Greens collection. The new products are Skin Greens Heat Is On CBD Gel, Skin Greens Cool Down CBD Gel, and Skin Greens Restore, Revive, Relax CBD Salve. Skin Greens CBD Gel Heat Is On combines a high concentration of cannabidiol (1.50 % of CBD) and seven additional powerful active ingredients (Glucosamine Hcl, Methyl Salicylate, Eucalyptus Globulus Essential Oil, Peppermint Essential Oil, Capsicum Frutescens Extract, Menthol, Camphor) providing calming care for arms, legs, neck, and back that relaxes and soot ..read more

CBD is safe and tolerable for short-term use for a maximum of 30 days at a maximum dose of 200 mg/day through oral administration, Health Canada’s scientific committee has decided. On the 28th of July 2022, the Science Advisory Committee on Health Products Containing Cannabis, asked by Health Canada to provide advice that would help shape regulations for health products containing cannabis in Canada, published their report. The nine-member Committee co-chaired by Dr. Paula Brown and Dr. Richard Huntsman contains ten recommendations for the safe use of cannabidiol (CBD). The Committee said it b ..read more

On 28th June 2022, the European Industrial Hemp Association (EIHA) representatives joined the info-session organized by the European Food Safety Authority (EFSA) in an attempt to foresee the reasons for any future delays in the approval of CBD novel food applications in the EU. In the EU, if food is considered novel, it must be authorized by the European Commission and undergo a pre-market safety assessment by the EFSA. So far, there is still no approval for any of the 130-plus natural CBD applications within the EU. On the other hand, the Commission has since moved forward with synthetic CBD ..read more

The first human study on the efficacy of topical CBD for the treatment of thumb basal joint arthritis-related pain published in May in the Journal of Hand Surgery found that topical CBD brings significant improvements in pain and disability without side effects. The opioid crisis has driven scientists into exploring more effective and safer solutions in the treatment of chronic pain, and CBD has become a serious candidate for such a role. Pain remains the main reason why consumers reach out to CBD products. In a 2021 survey of 253 participants, where 62.0% reported trying a CBD product, the ma ..read more

On June 7, 2022, the European Fooda Safety Authority (EFSA) published a statement summarising the state of knowledge on the safety of CBD consumption and highlighting areas where more data are needed. EFSA said that its scientists cannot currently establish the safety of cannabidiol (CBD) as a novel food due to data gaps and uncertainties about potential hazards related to CBD intake. EFSA’s expert Panel on Nutrition, Novel Foods and Food Allergens (NDA) has received 19 applications for CBD as a novel food, with more in the pipeline. Chair of the NDA Panel, Prof. Dominique Turck said: “We have ..read more